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Derivation and preliminary characterisation of adriamycin
resistant lines of human lung cancer cells
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MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge, CB2 2QH, UK.
Summary We have produced adriamycin (ADM)-resistant variants of the human lung cancer cell lines NCI-
H69 (small cell), MOR (adenocarcinoma) and COR-L23 (large cell) but have failed to produce resistant
variants of two other small cell lines. In each case, the derivation protocol took 7-9 months and included a
period of drug-free growth. All three resistant lines show reduced cellular content of ADM after 1 h exposure
when compared with their controls. During prolonged incubation of control and resistant NCI-H69 cells in
0.4 jgml- ADM, the ADM content of resistant cells was 6-7 times lower than that of control cells. The
ratio of ADM doses to suppress growth of the two lines, however, was in the range 40-200X. The ADM-
resistant variant of NCI-H69 was also resistant to vincristine, colchicine, VP16, mitozantrone, 4'epiadriamycin
and 4'deoxyadriamycin, somewhat resistant to melphalan but not resistant to aclacinomycin A, bleomycin or
CCNU. The resistance to ADM could be partially overcome by the use of verapamil, an inhibitor of calcium
transport.
There are numerous reports in the literature of the
development of cell lines which are resistant to the
anthracycline drugs daunorubicin and doxorubicin
(adriamycin, ADM). Most of these lines are either
leukaemias or ascites tumours of rodent origin
(Dano, 1972; Johnson et al., 1976; Nishimura et al.,
1978; Belli & Harris, 1979). Recently, however,
ADM-resistant sublines have been obtained from a
murine fibrosarcoma (Giavazzi et al., 1983) and
from human ovarian cancer lines (Hamilton et al.,
1983). A number of mechanisms of resistance have
been identified including defective drug
accumulation due to increased active efflux (Dano,
1973), increased intracellular glutathione (Babson et
al., 1981) and decreased amounts of cellular
enzymes (Mungikar et al., 1981). Adriamycin
resistance is closely associated with the
phenomenon of pleiotropic or multi-drug resistance
(Bech-Hansen et al., 1976) where collateral
resistance to vincristine and colchicine is observed.
This form of resistance is thought to be associated
with the presence in the cell membrane of a
glycoprotein of 170 K molecular weight (the p-
glycoprotein) (Ling, 1982) and a gene amplification
(Roninson et al., 1984).
As part of our laboratory studies of drug
resistance in human lung cancer, we wished to
produce adriamycin-resistant sub-lines of human
lung cancer cell lines. In this paper we describe the
derivation of such lines and their partial
characterisation.
Materials and methods
Cell lines and culture conditions
The cell lines used in this study were small cell line
NCI-H69 (kindly supplied by Dr D. Carney of the
NCI-Navy Medical Oncology Branch) and derived
from a patient who had previously received multi-
drug (including ADM) therapy, small cell lines
CORL-32 and CORL-47 derived in this laboratory
from previously untreated patients (Baillie-Johnson
et al., 1985), adenocarcinoma line MOR (kindly
supplied by Dr M. Ellison, Ludwig Institute,
Sutton) and large cell anaplastic line COR-L23
derived in this laboratory (Baillie-Johnson et al.,
1985). All three small cell lines grew as free-floating
aggregates of cells, whilst MOR and COR-L23
grew adherent to plastic.
All the lines were maintained in RPMI 1640
medium with 10% foetal calf serum, penicillin and
streptomycin (all Gibco Europe Ltd). Lines MOR
and COR-L23 were subcultured using a 15 min
exposure to trypsin (0.4%, Gibco Biocult) and
versene (0.02%, Gibco Biocult). Usually the small
cell lines were subcultured using mechanical
disaggregation but where a true single cell
suspension was required the trypsin/versene
combination was used. Lines were maintained in
either 25 cm2 or 75 cm2 tissue culture flasks
(Falcon) and at 37°C in an atmosphere of 8% CO,
and 92% air.
Isolation ofresistant sublines
Ist Series The initial methodology adopted in
attempting to isolate ADM-resistant sublines of our
various human lung lines was as follows. We first
of all ascertained the highest concentration of
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ADM in which cell numbers would increase. After
allowing them to grow in this concentration for a
period of 2-4 weeks we then doubled the
concentration. If cell multiplication continued we
doubled the concentration again after a further 2-4
weeks and so on. When a concentration was
reached at which cell multiplication was inhibited,
the cells were maintained at this concentration for
an indefinite period of time in order to allow a
resistant subline to emerge.
2nd Series In the second series of experiments,
when a concentration of ADM was reached at
which no significant growth was occurring, the cells
were allowed to remain at this concentration for a
period of 4 weeks and the ADM was then removed
from the medium. If and when cell numbers began
to increase, ADM was re-added to the medium at
the same concentration previously found to inhibit
growth. If the cells continued to multiply, step-
wise doubling of ADM concentration then
recommenced.
Drugs
Adriamycin (ADM) (Farmitalia), 4'deoxyadria-
mycin (4'DEOXY) (Farmitalia), 4'epiadriamycin
(4'EPI) (Farmitalia), vincristine (VCR) (Eli Lilly),
colchicine (COL) (Sigma), etoposide (VP16)
(Bristol-Meyers), and bleomycin (BLM) (Lundbeck)
were all dissolved in sterile water and aliquots
stored at -20°C. Aclacinomycin A (ACL)
(Lundbeck) was dissolved and stored at -20°C in
pr6pylene glycol and subsequently diluted in sterile
water immediately before use. Melphalan (MEL)
(Chester Beatty Research Institute) was dissolved in
acidified ethanol immediately before use. CCNU
(US National Cancer Institute) was dissolved in
absolute ethanol immediately before use.
Mitozantrone (MIT) (Lederle) was stored at room
temperature in its solvent as supplied and diluted in
sterile water immediately before use. All drugs were
added to cultures in volumes of 20-100 p1 into 5ml.
It has been previously shown that none of the
solvents alone cause inhibition of cell growth at
these concentrations.
Response experiments
In order to determine the drug sensitivity of the
lines NCI-H69, MOR and COR-L23 and their
ADM-resistant variants, a number of 6 cm diameter
tissue culture plastic petri dishes were set up each
containing 2 x 105 cells. Drugs were added to
various dishes at appropriate concentrations.
For NCI-H69 and its variants, bulk culture was
mechanically disaggregated and an aliquot of this
then reduced to a single cell suspension using
trypsin/versene. The aliquot was then counted and
on the basis of this count, the mechanically-
disaggregated suspension was diluted as
appropriate. For MOR and COR-L23 (and their
variants) cells for experiments were obtained from a
number of growth flasks using trypsin/versene.
Dishes were incubated for a period of time equal to
that needed for cells in control dishes to be
approaching the end of exponential phase growth
(6-8 days) as determined from growth curves.
Hence within a given experiment, dishes which
contained resistant variant cells were counted 1-2
days after dishes containing control cells. Cells from
each dish were harvested into a single cell
suspension using trypsin/versene and phase-contrast
viable cells were counted using a haemocytometer.
ADM-uptake experiments
The method used to determine ADM content per
cell was essentially that of Schwartz (1973). In
short-term experiments with NCI-H69 and its
resistant variants, incubation was carried out in
volumes of 2ml in polystyrene centrifuge tubes.
Each tube contained 2-5 x IO' cells ml-1 of a
mechanically-disaggregated suspension from a bulk
culture which had been medium changed 48 and
24h previously. Resistant variants were grown in
medium without ADM for 48 h before the
experiment. Appropriate concentrations of ADM
were added to the tubes and they were incubated at
37°C with agitation every 10min. After the
appropriate time (usually 1 h), the tubes were
centrifuged at room temperature for 5 min at 200g
and the medium removed. The cell pellet was rinsed
twice in complete medium at room temperature
with centrifugation as above. A volume of 0.2ml of
ice-cold sodium lauryl sulphate solution (0.1%) was
then added to each tube and the tubes vortexed. A
volume of 0.2ml of ice-cold silver nitrate solution
(33% w/v) was then added and the tubes were
shaken at 4°C for 10min. At the end of this time,
4ml of iso-amyl alcohol were added and a further
10min shaking carried out followed by
centrifugation for 5 min at 200g. The alcohol layer
from each tube was then transferred to a 5 ml pyrex
glass tube and fluorescence was measured in a
Perkin-Elmer MPF4 spectrofluorimeter with an
excitation wavelength of 490nm and an emission
wavelength of 595 nm. Standards were prepared by
adding appropriate amounts of ADM to tubes
containing untreated cells following the addition of
the silver nitrate solution.
Experiments with MOR and COR-L23 cells were
carried out by setting up a series of 25 cm2 flasks at
6 days before the experiments. Numbers of cells per
flask were adjusted so that flasks of parent cells and
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of cells at the time of the experiments. ADM
exposure and the double rinse were then carried out
on growing monolayers of cells and the cells
subsequently harvested using trypsin/versene,
counted on a haemocytometer and assayed for
ADM content as above.
Results
Isolation ofresistant sublines
In this section, serial microscopic observations on
cells in cultures are reported. For these purposes,
cultures are considered to be 'growing well' when
their rate of cell multiplication is approximately
equal to that seen in control cultures of the same
line. 'Slow growth' indicates that cell numbers at
least double over a period of one week. 'Viability' of
cells is based on their appearance under phase
contrast microscopy.
Ist Series In the first series of experiments the
results for the individual lines were:
NCI-H69
The cells would grow well in 0.01 jigml-1 of
ADM and relatively slowly at 0.02jgml-'. Slow
growth at 0.054ugml - was achieved by 14 weeks
and at 0.10pgml-F by 35 weeks. No growth at
0.20Mgml'- was achieved up to 1 year.
COR-L32 and COR-L47
Cells of line COR-L32 and COR-L47 would
grow well at 0.01 Mgml-' of ADM. COR-L32 was
transferred to 0.02Mgml-1 on several occasions
over a period of 6 months but never grew at this
concentration. COR-L47 was successfully
transferred to 0.02Mgm-1 but several attempts to
transfer to 0.05 Mgml1 were unsuccessful.
MOR and COR-L23
Cells of line MOR and COR-L23 would grow
at 0.05jigml-1 and 0.Oligml-l of ADM
respectively. Doubling of these concentrations,
however, always led to a cessation of growth.
2nd Series In view of the fact that in most
instances an ADM concentration was found at
which cells appeared to remain viable for a long
period of time but without significant increase in
cell numbers, an alternative approach of allowing
such cells to recover in the absence of drug was
tried.
NCI-H69
A subline of cells was started off at 0.02/Mgml-'
of ADM and transferred to 0.04Mgml-1 after 3
weeks. The culture became static and after a further
4 weeks the ADM was removed. Five weeks later
cell numbers began to increase and a healthy
rapidly growing culture was present by 10 weeks
after drug removal. ADM was re-introduced at
weekly increasing doses of 0.1, 0.2 and 0.4pgml-'
and cells were growing well in 0.4Mgml-1 after a
total of 13 weeks following re-addition of drug. The
sublines growing continuously in 0.10 and
0.40 gml-' have been designated H69/LX and
H69/LX4 respectively and have been used in most
experiments described below. Hence the total time
to obtain line H69/LX4 was around 7 months. We
have subsequently increased further the ADM
concentration for growth of this subline and now
have a population growing progressively (albeit
very slowly) in 4.0 ugmlg-'.
COR-L32 and COR-L47
Despite a series of attempts, using the strategy
above, resistant variants of these lines have not
emerged.
MOR and COR-L23
Line MOR was grown successively at 0.02, 0.05
and 0.1,ugml-P. At 0.2,ugml-', no growth was
observed and the drug was removed after 2 weeks.
Small areas of rapid cell growth were seen in the
monolayer after 5 weeks and ADM was re-added at
0.2Mgml-'. Good growth was observed at this
concentration after 6 weeks. The total time to
obtain this subline was hence about 7 months. The
line has since been adapted to 0.8Mgml-1 over an
additional 6 months.
The time course of resistance development for
COR-L23 was rather similar. Successful growth at
0.2Mgml-' was established again after a total time
of about 7 months. We have subsequently been
unable to increase any further the ADM
concentration for continued growth of this line.
Properties ofresistant lines - NCI-H69
In comparing the properties of parent line NCI-H69
with its ADM-resistant variants, the parent cells
(designated 'H69/P') were always maintained under
similar passage number and conditions as the
variants (designated 'H69/LX' and 'H69/LX4').
Growth rate A series of experiments was per-
formed in which 6cm diameter dishes of H69/P and
H69/LX4 cells were set up (2 x 105 cells in 5ml
medium) and cells in representative dishes counted
on successive days. The data from these experiments
were combined and exponential lines fitted by
computer to the points lying between 105 and
2 x 106 cells per flask, i.e. after an initial lag phase
and before entry to plateau phase. The doubling
times indicated by the computer fit were 39 (95%
CL=33-47)h for parent line H69/P, 54 (46-64)h
for resistant line H69/LX4 (in the absence of ADM)532 P.R. TWENTYMAN et al.
and 74 (65-88) h for resistant line H69/LX4 in the
presence of 0.4Mgml-' ADM.
Stability of resistance We tested the resistance to
ADM of subline H69/LX4 after 3 and 9 weeks
growth in the absence of drug. At 3 weeks the ID80
(see 'Drug Sensitivity' below) of H69/LX4 (drug
free) was 0.20jigml-P compared with 0.016 gml-1
for parent line H69/P and 0.4ygml-1 for H69/LX4
maintained in ADM. After 9 weeks the ID80 for
H69/LX4 (drug free) was 0.20ygml- 1 compared
with 0.018jigml-' for H69/P and 0.4pgml-1 for
H69/LX4 maintained in ADM. The resistance
factors [i.e. ID80 (resistant line)/ID80 (parent line)]
for H69/LX4 out of drug were therefore 12 and 11
after 3 and 9 weeks respectively compared with 25
and 22 for H69/LX4 in drug. Partial loss of
resistance therefore occurs within 3 weeks but no
further loss is seen between 3 and 9 weeks of drug-
free growth.
Drug sensitivity The relative sensitivity to ADM of
parent (H69/P) and resistant (H69/LX, H69/LX4)
cells is shown in Figure 1. For each subline, the
ID80 was calculated as the drug dose at which the
best line fitted by eye to the points crosses the level
at which the number of cells per dish is 20% of
control. We chose ID80 as (a) the response curves
were generally steepest lower down and (b) as
untreated cells increase their number by 10-20 x
over the period of experiment, the ID80 value
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Figure 1 Effect of continuous incubation with ADM
on the growth of cells of line NCI-H69. Dishes of cells
set up on day 0 at 2 x lIO cells/dish and counted on
day 7 (H69/P and H69/LX) or day 8 (H69/LX4). (0)
Parent line, H69/P; (A) Resistant line, H69/LX (grows
in 0.1 pgml-' ADM); (U) Resistant line, H69/LX4
(grows in 0.4ygml-1 ADM). Points are counts of cells
in a single dish. This is experiment 't' in Table I.
corresponds to at least one doubling by the treated
cells. Here in Figure 1 the ID80 values are 0.015,
0.06 and 0.55Mgml-1 for H69/P, H69/LX and
H69/LX4 respectively. The results of similar
experiments carried out for ADM and a variety of
other cytotoxic drugs are shown in Tables I and II.
It may be seen from Table I that values of ID80
for H69/P cells to ADM cover a range of 7 x (0.004
to 0.28). For the 16 values given the mean is 0.0141
(95% CL=0.0108-0.0174). There is thus a degree of
inherent variability in the system. We do not believe
Table I Resistance factors for ADM of Line NCI-H69 and its
ADM-resistant variants
ID80 (jugml-'1)
Resistance
Drug Expt H69/P H69/LX H69/LX4 factora
0.13
0.17
0.21
0.33
0.06
0.14
6.8
6.1
_ 26
- 30
4.0
- 28
>0.40
>0.40
>1.00
>0.50
1.10
0.90
1.20
0.55
0.37
0.31
>25
>22
>71
>23
92
225
57
37
74
24
Mean (s.e.) of six
expts (a-d, t, w)
= 16.8 (5.1)
Mean (s.e.) of six
expts (n, o, q, t, w, x)
=84.8 (30.4)
'Resistance factor =ID80 (resistant line)
ID80 (parent line)
0.019
0.028
0.008
0.011
0.015
0.005
ADM a
b
c
d
t
w
g
i
m
n
0
q
t
w
x
0.016
0.018
0.014
0.022
0.012
0.004
0.021
0.015
0.005
0.013
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Table II Relative resistance of ADM-resistant variants to other drugs
ID80 (ygm1-')
Resistance
Drug Expt H69/P H69/LX H69/LX4 factora
VCR f 0.002 - >0.1 >50
j 0.006 - >0.1 > 17
1 0.0017 - 1.8 1060
COL k 0.004 - 0.26 65
1 0.0025 - 0.24 96
BLM f 1.1 1.4 - 1.3
j 3.5 - 2.9 0.8
ACL b 0.039 0.044 - 1.1
d 0.035 0.025 - 0.7
w 0.062 0.049 - 0.8
w 0.062 - 0.14 2.3
MIT s 0.0036 - >0.020 >5.6
v 0.0068 - 0.10 14.7
VP16 s 0.18 - >0.40 >2.2
u 0.08 - 7.0 88
4'EPI m 0.017 - >0.5 >29
n 0.009 - > 1.0 >110
4'DEOXY m 0.007 - 0.31 44
n 0.003 - 0.45 150
MEL h 0.26 0.16 - 0.6
x 0.25 - 1.1 4.4
y 0.45 - 1.0 2.2
CCNU h 1.5 0.60 - 0.4
x 0.69 - 0.74 1.1
The lettering of individual experiments enables a direct comparison
of results obtained for each drug with the result for ADM in the same
experiment. The experiments were carried out in alphabetical order
over a period of 10 months.
'Resistance factor =ID80 (resistant line)
ID80 (parent line)
that the counting of a single cell population at each
drug dose is a major factor - preliminary
experiments showed that replicate dishes at a given
dose gave very similar counts. Part of the
variability results from the fact that drug doses are
logarithmically spaced. In addition, however,
unexplained factors concerned with the biological
state of the test cells at the time of individual
experiments must be involved.
The data in Table II indicate that ADM-resistant
variants of the NCI-H69 small cell line are also
highly resistant to VCR, COL, 4'EPI, 4'DEOXY,
MIT and VP16, somewhat resistant to MEL, but
NOT resistant to BLM, ACL or CCNU.
Comparison with other lung cancer lines Accumu-
lated data from a number of experiments to
determine the ADM sensitivity of a range of lung
cancer lines are shown in Figure 2. In addition to
the lines described in Materials and methods, also
included are COR-L51, COR-L88 and H2Fd. The
first of these is a small cell line from an untreated
patient; the second is a small cell line from a patient
with recurrent disease following multi-drug chemo-
therapy (Baillie-Johnson et al., 1985) and the
third is a subline from a small cell line (MAR)
which had been treated three times in vitro with
ADM to a low level of survival and allowed to
regrow. It may be seen that the data for all lines
other than H69/LX4 can be covered by a factor of
5 x in ADM sensitivity and that the sensitivity of
line H69/LX4 is totally outside this range.
Effect of verapamil To investigate whether the
calcium channel blocker, verapamil, could overcome
the resistance to ADM, a series of experiments was534 P.R. TWENTYMAN et al.
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Figure 2 Effect of continuous incubation with ADM
on the growth ofcells from various lung cancer lines. The
lines are fitted by eye to the data for NCI-H69 parent
(H69/P) cells (@) and ADM-resistant (H69/LX4) cells
(U). Each point represents the count ofcells from a single
dish. (A) COR-L47; (A) COR-L51; (V) H2Fd; (V)
COR-L88; (0) MOR; (C1) COR-L23.
carried out as previously described but with the
addition of 6.6 pM verapamil to matched dishes.
This dose of verapamil has been extensively used by
others (Tsuruo et al., 1983a, b) in this type of
investigation and we found it to have no growth
inhibitory effects on its own. We were in fact able
to use doses of verapamil alone as high as 30 4uM
without causing significant inhibition of growth in
H69/P cells. The results are shown in Table III. It
may be seen that in all three experiments, the
addition of verapamil led to a large but not total
removal of resistance from line H69/LX4 whilst
having little or no effect on the sensitivity of H69/P
cells.
Table III Effect of 6.6,uM verapamil on ADM sensitivity
ID80 (9gml 1)
Resistance
Drug Expt H69/P H69/LX4 factor
ADM o 0.0040 0.90 225
ADM+VERAP o 0.0030 0.046 15.3
ADM q 0.021 1.2 57
ADM+VERAP q 0.015 0.11 7.3
ADM z 0.0098 1.4 143
ADM+VERAP z 0.0090 0.16 17.7
Cellular pharmacokinetics Initial experiments (not
shown) indicated that when cells were exposed at
105cellsml-' to 10pgml-1 of ADM, the ADM
content per cell rose over the first 15-30min but
did not increase further as the time was increased to
1 h. Subsequent experiments have, therefore,
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Figure 3 ADM content of NCI-H69 cells incubated
with drug for a period of 1 h. (0) Parent (H69/P) cells;
(-) Resistant (H69/LX4) cells.
compared the ADM content per cell of H69/P and
H69/LX4 cells exposed to ADM for 1 h in order to
determine the equilibrium content for short-term
exposure. The data from a typical experiment are
shown in Figure 3. The ADM content of resistant
subline H69/LX4 was around half of that in parent
line H69/P. Similar results were obtained in three
replicate experiments although the absolute levels of
uptake were different between experiments.
We additionally determined the ADM content of
H69/P and H69/LX4 cells when exposed to
0.4pgml-1 of ADM for 24 or 48h. (This is the
ADM concentration in which subline H69/LX4 is
maintained.) In the first experiment incubation was
carried out at 1.3 x 106 cells in 5 ml whilst in the
second, 1 x 106 cells in 5ml was used. The results
are shown in Table IV. It may be seen that H69/P
cells had around 6 times the ADM content of
H69/LX4 cells at both 24 and 48 h in the first
experiment, and that the ratio in the second
experiment was very similar.
Properties of resistant lines - MOR and COR-
L23 Parent lines of adenocarcinoma MOR and
large cell carcinoma COR-L23 were compared with
their ADM-resistant variants with regard to ADM
sensitivity and ADM content after short-term
exposure. The variants used in these studies were
MOR (0.2R) and COR-L23 (0.2R) both selected for
growth in 0.2 pgml-' of ADM.
Figure 4 shows the data from one cell growth
experiment. For MOR and its resistant variant the
ratio of ID80 values was 7.7 whereas for COR-L23
and its resistant variant, the ratio was 12.3. In a
repeat experiment the ratios were 3.1 and 7.8
respectively. The ADM contents of cells exposed to
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Table IV ADM content of cells during long-term
incubation in 0.4Mgml-I
Time of ADM (,ug10-' cells)a Ratio
incubation H69/P
Expt (h) H69/P H69/LX4 H69/LX4
A 24 3.89 0.60 6.5
48 5.48 0.92 6.0
B 24 6.16 0.97 6.4
Values of ADM content are means of three replicate
samples.
aThese values are based on the numbers of cells
originally inoculated into the dishes. After 24h, the total
number of phase-contrast viable cells recovered from both
H69/P and H69/LX4 was within 20% of the initial
inoculum. By 48 h, however, only 50% of the original cell
number could be recovered from dishes of H69/P in which
ADM (0.4Mgml-') was present. No such reduction was
seen, however, for H69/LX4. The ratio of cellular content
given for 48 h is, therefore, probably an underestimate of
the true ratio based on ADM/viable cell at the time of
assay.
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Figure 4 Effect of continuous incubation with ADM
on the growth of cells of lines MOR and COR-L23.
Dishes of cells set up on day 0 at 2 x 105 cells/dish and
counted on day 6 (except COR-L23 resistant, set up at
3 x 105 cells/dish). Each point represents count of cells
from a single dish. (A) COR-L23 parent; (A) COR-
L23 ADM (0.2 Mgml-1) resistant; (V) MOR parent;
(V) MOR ADM (0.2pgml- ) resistant.
ADM for 1 h are shown in Figure 5. A repeat
experiment (not shown) gave very similar results. It
may be seen that both MOR and COR-L23 had
clearly reduced content of ADM compared with the
respective parent lines.
Discussion
In this paper we have described the isolation and
partial characterisation of ADM-resistant variants
2u
e15
u
0
1-~
a)
o
C.
0 5
A
v
I/
A~
_ _ - y _ _
0 5 10
ADM (jig ml-')
15
Figure 5 ADM content of MOR and COR-L23 cells
incubated with drug for 1 h. (-) COR-L23 parent; (A)
COR-L23 ADM (0.2 ygml 1) resistant; (V) MOR;
(V) MOR ADM (0.2pgml-1) resistant.
of three human lung cancer cell lines. A variety of
techniques have been used by other workers to
produce ADM-resistant sublines of murine cells
including growth in low concentrations for many
months followed by cloning (Belli & Harris, 1979),
a double cloning over 6-8 weeks (Hill et al., 1985)
or growth of cells in rapidly increasing
concentrations of ADM over 6-8 weeks (Giavazzi
et al., 1983). We were able to obtain an ADM-
resistant subline of the EMT6 mouse tumour cell
line by growth in vitro in increasing concentrations
of ADM over 6 weeks. For our human lung lines,
however, it was only possible to derive ADM-
resistant sublines of NCI-H69, MOR and COR-L23
by including a period of drug-free growth in the
derivation step. For two other small cell lines COR-
L32 and COR-L47, we were unable to produce
ADM-resistant sublines by any of the strategies
used. This difference may reflect the generally
longer cycle time of the human cells (e.g. 39h for
NCI-H69 compared with <20 h for the rodent lines).
It may also reflect the relative sensitivities of the
major component of ADM-sensitive and a minor
sub-population of ADM-resistant cells present in
the various parent populations. Whether or not the
drug itself is able to induce mutations leading to
resistance is not known but if this mechanism does
occur, the frequency of such mutations may differ
between lines. Because of the difficulty encountered
in obtaining resistant sublines of the human cells, it
seemed possible that the mechanism of the
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resistance obtained may differ from that in the
rodent cells described by others. It is clear from the
data presented, however, that the patterns of cross-
resistance and changes in ADM accumulation
closely resemble those seen in rodent cells.
The ADM-resistant subline of NCI-H69 was also
resistant to colchicine, vincristine and VP16. This is
in agreement with the general pattern of 'pleiotropic
drug resistance' which has been previously
described (Bech-Hansen et al., 1976; Biedler et al.,
1983; Giavazzi et al., 1983).
Cross-resistance of ADM-resistant lines to VP16
and to mitozantrone has also been reported for in
vivo systems by Schabel et al. (1983). Lack of cross-
resistance to BLM by ADM-resistant lines has also
been previously described (Bech-Hansen et al., 1976;
Giavazzi et al., 1983). A lack of cross-resistance to
ACL in ADM-resistant L5178 mouse cells has been
reported by Hill et al. (1985) and the data of
Schabel et al. (1983) are suggestive that ADM
resistant cells may be less than fully cross-resistant
to ACL. Similarly, data for CCNU are not available
but the closely related nitrosourea BCNU was
found to be fully active against an ADM-resistant
line (Schabel et al., 1983). The published data for
MEL are conflicting. In the study of Elliot and
Ling (1981), their ADM-resistant CHO cell was
found to be significantly resistant to MEL, whereas
the MEL sensitivity of parent and ADM-resistant
lines was similar in the study by Schabel et al.
(1983). Our results indicate that some degree of
resistance to MEL occurs in fully resistant NCI-
H69 cells. The ADM analogues, 4'EPI and
4'DEOXY have previously been studied by Hill et
al. (1985) and whereas the former agent was found
to ge fully cross-resistant with ADM, there was no
cross-resistance with the latter agent. In our studies
reported here, however, cross-resistance was seen
with both drugs. In general therefore the cross-
resistance patterns shown by our ADM-resistant
human cells are similar to results previously
described by others for rodent cells. The lack of
cross-resistance for ACL is of particular interest to
us as we and others have recently reported
preliminary observations on lack of cross-resistance
between ADM and a family of novel anthracyclines
recently synthesised by Roche Products Ltd
(Twentyman et al., 1985; Scott et al., 1985). Our
studies on structure/activity relationship for these
compounds and on the mechanism of cytotoxicity
are continuing.
Our observations that ADM-resistant human
lung cancer cells show a reduced drug content after
a given exposure are in accordance with previous
observations on rodent cells (Kessel et al., 1968;
Dano, 1973). The reduced ADM content is believed'
to be due to an increased efficiency of active drug
efflux (Skovsgard, 1978; Inaba et al., 1979). Use of
the calcium transport blocker, verapamil, to block
such active efflux has been described by Tsuruo et
al. (1982, 1983a, b). It is interesting that the
equilibrium content of ADM in H69/P and
H69/LX4 variants of NCI-H69 cells differs by only
around a factor of 6 x whereas the ratio of ADM
doses to suppress growth lies in the range 40-200 x.
Studies of the relationship between cellular ADM
accumulation and cytotoxicity are currently in
progress and will shed light on the significance of
this observation.
A number of studies have indicated that multi-
drug resistance is frequently associated with gene
amplification and changes in cellular protein
compostion (Ling, 1982; Beck, 1983, Biedler et al.,
1983; Kartner et al., 1983; Robinson et al., 1984).
Our continuing studies are therefore directed
towards identification and characterisation of
genetic changes and associated differences in protein
composition in normal and drug-resistant human
lung cancer cells.
We are grateful to Lundbeck Ltd. for supplies of
Alacinomycin A and to Farmitalia Carlo Erba for
4'epiadriamycin and 4'deoxyadriamycin.
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